Both behavioral activation psychotherapy and antidepressant medication management reduce depressive symptoms by about 50 percent
No significant changes seen in new prescriptions for antidepressants, benzodiazepines, or buprenorphine for opioid use disorder
No association seen between cannabis use and nonmedical opioid use in those receiving pharmacotherapies for OUD
However, the agency noted officials cannot rule out that 'a small risk may exist,' and it will continue to investigate
Functioning and mental health benefits sustained at one-month follow-up
Strongest demographic predictor for discharge initiation of medications for alcohol use disorder was younger age
No increased risk for suicidal ideation seen with semaglutide versus non-GLP1R agonist antiobesity medications
FDA is investigating reports of hair loss, aspiration, and suicidal thoughts among people taking the medications
Dulaglutide effective in preventing substantial weight gain, which was more common in women
Autism, substance-related disorders, disruptive disorders were diagnoses with highest rates of pharmacologic restraint days